Tom Powles: Perhaps the most important long-term bladder cancer data at ASCO24

Tom Powles, Director of Barts Cancer Center, shared on X/Twitter:

”Perhaps the most important long-term bladder cancer data at ASCO24. Neoadjuvant, Toripalimab and disitimab Vedotin in muscle invasive bladder cancer (n=47). pCR increased by 63%. 14% G3/4 AEs. All surgeries occurred . The 1st MMAE/IO neoadjuvant combo data looks. EV/IO MIBC trials awaited.”

Source: Tom Powles/X